👪

Inheritance

2

X-linked inheritance in IGSF1, TBL1X, and IRS4-related isolated disease HP:0001417

Several established isolated central congenital hypothyroidism genes are X-linked, so affected males may be preferentially recognized in these families.

X-linked inheritance

Show evidence (1 reference)

PMID:38462462 SUPPORT Human Clinical

"The results revealed IGSF1 and TBL1X pathogenic variants in nine and one patient, respectively."

This Japanese survey supports X-linked gene involvement through IGSF1 and TBL1X pathogenic variants in isolated central congenital hypothyroidism.

Autosomal recessive inheritance in TSHB and TRHR-related isolated disease HP:0000007

TSHB and TRHR-related isolated central congenital hypothyroidism can follow autosomal recessive inheritance, including homozygous variants in affected children from carrier or consanguineous families.

Autosomal recessive inheritance

Show evidence (2 references)

PMID:28419241 SUPPORT Human Clinical

"Thyrotropin-releasing hormone (TRH) receptor (TRHR) defects are rare recessive disorders usually associated with incidentally identified CCH and short stature in childhood."

This directly supports recessive TRHR-related central congenital hypothyroidism.

PMID:28515030 SUPPORT Human Clinical

"Both patients were homozygous and the parents were heterozygous."

Homozygous affected siblings with heterozygous parents support recessive TSHB-related isolated central congenital hypothyroidism.

⚙

Pathophysiology

3

Impaired Hypothalamic-Pituitary TSH Drive

The proximal defect is inadequate hypothalamic or pituitary control of thyroid function. Reduced TRH signaling, pituitary thyrotroph dysfunction, or pathogenic variants in isolated CCH genes can leave TSH biologically or quantitatively insufficient for normal neonatal thyroid hormone production.

thyrotroph link

Thyroid-stimulating hormone secretion link ↓ DECREASED Regulation of thyroid-stimulating hormone secretion link ⚠ ABNORMAL

hypothalamus-pituitary axis link pituitary gland link

Downstream

Reduced Thyroid Hormone Generation Inadequate TSH drive limits thyroid hormone production, producing low free thyroxine despite absent or blunted TSH elevation.

Show evidence (1 reference)

PMID:39913280 SUPPORT Human Clinical

"Central CH is caused by insufficient pituitary or hypothalamic control of thyroid function, biochemically characterized by a low serum free thyroxine (fT4), in combination with a low, normal or mildly elevated thyroid-stimulating hormone (TSH)."

This review directly defines the central hypothalamic-pituitary mechanism and the diagnostic hormone pattern.

Reduced Thyroid Hormone Generation

Low free thyroxine from birth reduces thyroid-hormone-dependent metabolic and neurodevelopmental signaling during a period when thyroid hormone is required for brain development.

Thyroid hormone generation link ↓ DECREASED Response to thyroid hormone link ↓ DECREASED

thyroid gland link

Show evidence (1 reference)

PMID:37326450 SUPPORT Human Clinical

"Thyroid hormone (TH) is indispensable for brain development in utero and during the first 2-3 years of life, and the negative effects of TH deficiency on brain development are irreversible."

This supports thyroid hormone deficiency as a mechanistic risk for early neurodevelopmental injury.

Multiple Pituitary Hormone Deficiency Context

Central congenital hypothyroidism commonly occurs with other pituitary hormone deficiencies. Coexisting ACTH and growth hormone deficiency can add acute risk through severe hypoglycemia and adrenal crisis, making pituitary evaluation clinically important.

corticotroph link somatotroph link

Pituitary gland development link ⚠ ABNORMAL

pituitary gland link

Show evidence (2 references)

PMID:39913280 SUPPORT Human Clinical

"Central CH is less common than primary CH and is part of multiple pituitary hormone deficiencies (MPHD) in most of the cases."

This supports modeling a frequent MPHD-related mechanism alongside isolated monogenic central congenital hypothyroidism.

PMID:39913280 SUPPORT Human Clinical

"MPHD at birth, also known as 'congenital hypopituitarism', is a potentially life-threatening condition due to the possible co-occurrence of adrenocorticotropin hormone and growth hormone deficiency that can result in severe hypoglycemia and adrenal crisis."

This gives the clinical consequence of coexisting ACTH and GH deficiency in congenital hypopituitarism.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

10

Digestive 1

Prolonged Neonatal Jaundice Prolonged neonatal jaundice (HP:0006579)

Show evidence (1 reference)

PMID:42048107 SUPPORT Human Clinical

"Non-specific neonatal concerns (hypoglycaemia/jaundice/weight concerns, 83%) and significant neurodevelopmental defects (34%) occurred frequently."

The cohort explicitly includes jaundice among frequent nonspecific neonatal concerns.

Endocrine 1

Pituitary Hypoplasia Anterior pituitary hypoplasia (HP:0010627)

Show evidence (1 reference)

PMID:38462462 SUPPORT Human Clinical

"Two of the four variant-negative patients and a variant-positive patient were diagnosed with pituitary hypoplasia."

This directly reports pituitary hypoplasia in the Japanese isolated central congenital hypothyroidism survey.

Genitourinary 1

Macroorchidism Or Testicular Enlargement Macroorchidism (HP:0000053)

Show evidence (1 reference)

PMID:38299175 SUPPORT Human Clinical

"Only the older brother had prolactin deficiency and testicular growth without elevated testosterone levels."

This supports testicular enlargement as an IGSF1-related associated feature; the HPO term is the closest phenotype-level mapping.

Growth 2

Obesity Obesity (HP:0001513)

Show evidence (1 reference)

PMID:38462462 SUPPORT Human Clinical

"One and two patients with IGSF1 variant had obesity and intellectual disability, respectively."

This supports obesity as an associated phenotype in IGSF1-related isolated central congenital hypothyroidism.

Short Stature Or Reduced Growth Rate In IGSF1 Deficiency Short stature (HP:0004322)

Show evidence (1 reference)

PMID:38299175 SUPPORT Human Clinical

"School checkups revealed that the older brother was overweight and had a reduced growth rate at the age of 11 yr, whereas the younger brother was overweight and had short stature at the age of 8 yr."

This sibling case report directly supports growth failure and short stature as features prompting diagnosis in IGSF1 deficiency.

Other 5

Low Free Thyroxine With Non-Elevated TSH

Show evidence (1 reference)

PMID:39913280 SUPPORT Human Clinical

"Central CH is caused by insufficient pituitary or hypothalamic control of thyroid function, biochemically characterized by a low serum free thyroxine (fT4), in combination with a low, normal or mildly elevated thyroid-stimulating hormone (TSH)."

The abstract states the biochemical pattern used to recognize central congenital hypothyroidism.

Congenital Hypothyroidism Congenital hypothyroidism (HP:0000851)

Show evidence (1 reference)

PMID:39913280 SUPPORT Human Clinical

"Congenital hypothyroidism (CH) is defined as thyroid hormone deficiency at birth and constitutes one of the most common causes of preventable intellectual disability worldwide."

This supports the congenital hypothyroidism phenotype and the rationale for early detection.

Neonatal Hypoglycemia Neonatal hypoglycemia (HP:0001998)

Show evidence (1 reference)

PMID:42048107 SUPPORT Human Clinical

"Non-specific neonatal concerns (hypoglycaemia/jaundice/weight concerns, 83%) and significant neurodevelopmental defects (34%) occurred frequently."

The UK cohort reports hypoglycemia among frequent nonspecific neonatal concerns in clinically diagnosed cases.

Neurodevelopmental Abnormality Neurodevelopmental abnormality (HP:0012759)

Show evidence (1 reference)

PMID:42048107 SUPPORT Human Clinical

"Non-specific neonatal concerns (hypoglycaemia/jaundice/weight concerns, 83%) and significant neurodevelopmental defects (34%) occurred frequently."

This cohort directly reports neurodevelopmental defects in a substantial fraction of clinically diagnosed cases.

Reduced Circulating Prolactin Concentration Reduced circulating prolactin concentration (HP:0008202)

Show evidence (1 reference)

PMID:38299175 SUPPORT Human Clinical

"Only the older brother had prolactin deficiency and testicular growth without elevated testosterone levels."

This directly supports prolactin deficiency in one affected sibling with IGSF1 deficiency.

🧬

Genetic Associations

3

Established isolated central congenital hypothyroidism genes

Show evidence (3 references)

PMID:38462462 SUPPORT Human Clinical

"The results revealed IGSF1 and TBL1X pathogenic variants in nine and one patient, respectively."

This supports pathogenic variants in IGSF1 and TBL1X among isolated central congenital hypothyroidism patients.

PMID:38462462 SUPPORT Human Clinical

"The study revalidated that IGSF1 variants comprise the most frequent pathogenic variant in patients with isolated central CH in Japan."

This supports IGSF1 as the leading identified genetic cause in that Japanese isolated central congenital hypothyroidism cohort.

PMID:38299175 SUPPORT Human Clinical

"The siblings harbored a novel nonsense variant in exon 16 of IGSF1 (NM_001555.5: c.3056G>A: p.Trp1019Ter) and were diagnosed with IGSF1 deficiency."

This provides a concrete pathogenic IGSF1 variant example in sibling cases.

TSHB pathogenic variants

Autosomal recessive

Show evidence (1 reference)

PMID:28515030 SUPPORT Human Clinical

"However, mutations of the thyrotropin-releasing hormone receptor or thyroid-stimulating hormone-beta (TSHB) gene are responsible for isolated CCH."

This abstract directly identifies TSHB mutations as a cause of isolated central congenital hypothyroidism.

TRHR pathogenic variants

Autosomal recessive

Show evidence (2 references)

PMID:28419241 SUPPORT Human Clinical

"CONTEXT: Central congenital hypothyroidism (CCH) is an underdiagnosed disorder characterized by deficient production and bioactivity of thyroid-stimulating hormone (TSH) leading to low thyroid hormone synthesis."

This establishes the central congenital hypothyroidism context for the TRHR mutation study.

PMID:28419241 SUPPORT Human Clinical

"A unique missense TRHR defect identified in a consanguineous family is associated with central hypothyroidism in homozygotes and hyperthyrotropinemia in heterozygotes, suggesting compensatory elevation of TSH with reduced biopotency."

This directly supports TRHR pathogenic variation causing central hypothyroidism in homozygotes.

💊

Treatments

2

Levothyroxine Replacement

Action: Pharmacotherapy NCIT:C15986

Agent: levothyroxine ↗

Thyroid hormone replacement is the core treatment after diagnosis. In possible MPHD, clinicians must also consider adrenal insufficiency before or during thyroid hormone replacement.

Mechanism Target:

MODULATES Reduced Thyroid Hormone Generation — Levothyroxine replacement bypasses deficient endogenous thyroid hormone generation by supplying thyroid hormone pharmacologically.

Show evidence (1 reference)

PMID:36761493 PARTIAL Human Clinical

"Newborn screening (NBS) for congenital hypothyroidism (CH) was started in 1979 in Japan, and early diagnosis and treatment improved the intelligence prognosis of CH patients."

This supports early treatment benefit for congenital hypothyroidism generally, while the specific levothyroxine mechanism is standard endocrine inference from thyroid hormone replacement.

Target Phenotypes: Congenital hypothyroidism ↗

Show evidence (1 reference)

PMID:36761493 PARTIAL Human Clinical

"Newborn screening (NBS) for congenital hypothyroidism (CH) was started in 1979 in Japan, and early diagnosis and treatment improved the intelligence prognosis of CH patients."

This guideline abstract supports early treatment for congenital hypothyroidism generally; the specific levothyroxine management details are inferred from standard endocrine care rather than directly stated in the abstract.

Central Congenital Hypothyroidism-Capable Newborn Screening

Action: disease screening MAXO:0000124

T4-inclusive newborn screening with reflex TSH and TBG is a secondary prevention strategy that can detect central congenital hypothyroidism early.

Target Phenotypes: Congenital hypothyroidism ↗

Show evidence (2 references)

PMID:39913280 SUPPORT Human Clinical

"To date, central CH is the only pituitary hormone deficiency suitable for newborn screening (NBS), providing an opportunity for early detection of MPHD."

This supports newborn screening as a clinically relevant detection strategy for central congenital hypothyroidism and associated MPHD.

PMID:37326450 SUPPORT Human Clinical

"In the Netherlands, we have a unique T4-TSH-thyroxine-binding globulin (TBG) NBS algorithm for CH, which enables the detection of primary and central CH."

This supports a concrete T4-TSH-TBG screening implementation.

🔬

Biochemical Markers

2

Low Free Thyroxine (Present)

Context: Diagnostic thyroid function testing

Show evidence (1 reference)

PMID:39913280 SUPPORT Human Clinical

"Central CH is caused by insufficient pituitary or hypothalamic control of thyroid function, biochemically characterized by a low serum free thyroxine (fT4), in combination with a low, normal or mildly elevated thyroid-stimulating hormone (TSH)."

This exact abstract sentence states the free-thyroxine abnormality and the inappropriately non-elevated TSH pattern.

Normal, Low, Or Mildly Elevated TSH (Present)

Context: Diagnostic thyroid function testing

Show evidence (1 reference)

PMID:37326450 SUPPORT Human Clinical

"Most newborn screening (NBS) programs for CH are primarily TSH based and thereby do not detect central CH."

This supports the diagnostic limitation of TSH-based screening in central congenital hypothyroidism.

{ }

Source YAML

click to show

name: Central Congenital Hypothyroidism
creation_date: "2026-05-10T15:03:39Z"
updated_date: "2026-05-10T15:26:36Z"
category: Mendelian
disease_term:
  preferred_term: central congenital hypothyroidism
  term:
    id: MONDO:0016410
    label: central congenital hypothyroidism
parents:
- permanent congenital hypothyroidism
- central hypothyroidism
synonyms:
- Central CH
- congenital central hypothyroidism
- hypothalamic-pituitary hypothyroidism
- secondary hypothyroidism
- thyroid stimulating hormone deficiency
- thyrotropin deficiency
description: >-
  Central congenital hypothyroidism is congenital thyroid hormone deficiency
  caused by insufficient hypothalamic or pituitary stimulation of thyroid
  hormone production. Its core biochemical signature is low free thyroxine with
  a TSH concentration that is low, normal, or only mildly elevated relative to
  the degree of hypothyroxinemia.
inheritance:
- name: X-linked inheritance in IGSF1, TBL1X, and IRS4-related isolated disease
  inheritance_term:
    preferred_term: X-linked inheritance
    term:
      id: HP:0001417
      label: X-linked inheritance
  description: >-
    Several established isolated central congenital hypothyroidism genes are
    X-linked, so affected males may be preferentially recognized in these
    families.
  evidence:
  - reference: PMID:38462462
    reference_title: Clinical and molecular analyses of isolated central congenital hypothyroidism based on a survey conducted in Japan.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The results revealed IGSF1 and TBL1X pathogenic variants in nine and one patient, respectively."
    explanation: >-
      This Japanese survey supports X-linked gene involvement through IGSF1 and
      TBL1X pathogenic variants in isolated central congenital hypothyroidism.
- name: Autosomal recessive inheritance in TSHB and TRHR-related isolated disease
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >-
    TSHB and TRHR-related isolated central congenital hypothyroidism can follow
    autosomal recessive inheritance, including homozygous variants in affected
    children from carrier or consanguineous families.
  evidence:
  - reference: PMID:28419241
    reference_title: Central Hypothyroidism Due to a TRHR Mutation Causing Impaired Ligand Affinity and Transactivation of Gq.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Thyrotropin-releasing hormone (TRH) receptor (TRHR) defects are rare recessive disorders usually associated with incidentally identified CCH and short stature in childhood."
    explanation: >-
      This directly supports recessive TRHR-related central congenital
      hypothyroidism.
  - reference: PMID:28515030
    reference_title: Congenital Central Hypothyroidism Caused by a Novel Thyroid-Stimulating Hormone-Beta Subunit Gene Mutation in Two Siblings.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Both patients were homozygous and the parents were heterozygous."
    explanation: >-
      Homozygous affected siblings with heterozygous parents support recessive
      TSHB-related isolated central congenital hypothyroidism.
pathophysiology:
- name: Impaired Hypothalamic-Pituitary TSH Drive
  description: >-
    The proximal defect is inadequate hypothalamic or pituitary control of
    thyroid function. Reduced TRH signaling, pituitary thyrotroph dysfunction,
    or pathogenic variants in isolated CCH genes can leave TSH biologically or
    quantitatively insufficient for normal neonatal thyroid hormone production.
  locations:
  - preferred_term: hypothalamus-pituitary axis
    term:
      id: UBERON:0004092
      label: hypothalamus-pituitary axis
  - preferred_term: pituitary gland
    term:
      id: UBERON:0000007
      label: pituitary gland
  cell_types:
  - preferred_term: thyrotroph
    term:
      id: CL:0000476
      label: thyrotroph
  biological_processes:
  - preferred_term: Thyroid-stimulating hormone secretion
    term:
      id: GO:0070460
      label: thyroid-stimulating hormone secretion
    modifier: DECREASED
  - preferred_term: Regulation of thyroid-stimulating hormone secretion
    term:
      id: GO:2000612
      label: regulation of thyroid-stimulating hormone secretion
    modifier: ABNORMAL
  evidence:
  - reference: PMID:39913280
    reference_title: "Newborn screening for central congenital hypothyroidism: past, present and future."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Central CH is caused by insufficient pituitary or hypothalamic control of thyroid function, biochemically characterized by a low serum free thyroxine (fT4), in combination with a low, normal or mildly elevated thyroid-stimulating hormone (TSH)."
    explanation: >-
      This review directly defines the central hypothalamic-pituitary mechanism
      and the diagnostic hormone pattern.
  downstream:
  - target: Reduced Thyroid Hormone Generation
    causal_link_type: DIRECT
    description: >-
      Inadequate TSH drive limits thyroid hormone production, producing low
      free thyroxine despite absent or blunted TSH elevation.
    evidence:
    - reference: PMID:37326450
      reference_title: "Neonatal screening for primary and central congenital hypothyroidism: is it time to go Dutch?"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Central CH is characterized by low TH concentrations, while TSH is normal, low or slightly elevated."
      explanation: >-
        This independently supports low thyroid hormone with an inappropriately
        non-elevated TSH response as the downstream hormone output.
- name: Reduced Thyroid Hormone Generation
  description: >-
    Low free thyroxine from birth reduces thyroid-hormone-dependent metabolic
    and neurodevelopmental signaling during a period when thyroid hormone is
    required for brain development.
  locations:
  - preferred_term: thyroid gland
    term:
      id: UBERON:0002046
      label: thyroid gland
  biological_processes:
  - preferred_term: Thyroid hormone generation
    term:
      id: GO:0006590
      label: thyroid hormone generation
    modifier: DECREASED
  - preferred_term: Response to thyroid hormone
    term:
      id: GO:0097066
      label: response to thyroid hormone
    modifier: DECREASED
  evidence:
  - reference: PMID:37326450
    reference_title: "Neonatal screening for primary and central congenital hypothyroidism: is it time to go Dutch?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Thyroid hormone (TH) is indispensable for brain development in utero and during the first 2-3 years of life, and the negative effects of TH deficiency on brain development are irreversible."
    explanation: >-
      This supports thyroid hormone deficiency as a mechanistic risk for early
      neurodevelopmental injury.
- name: Multiple Pituitary Hormone Deficiency Context
  description: >-
    Central congenital hypothyroidism commonly occurs with other pituitary
    hormone deficiencies. Coexisting ACTH and growth hormone deficiency can add
    acute risk through severe hypoglycemia and adrenal crisis, making pituitary
    evaluation clinically important.
  locations:
  - preferred_term: pituitary gland
    term:
      id: UBERON:0000007
      label: pituitary gland
  cell_types:
  - preferred_term: corticotroph
    term:
      id: CL:0002309
      label: corticotroph
  - preferred_term: somatotroph
    term:
      id: CL:0002312
      label: somatotroph
  biological_processes:
  - preferred_term: Pituitary gland development
    term:
      id: GO:0021983
      label: pituitary gland development
    modifier: ABNORMAL
  evidence:
  - reference: PMID:39913280
    reference_title: "Newborn screening for central congenital hypothyroidism: past, present and future."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Central CH is less common than primary CH and is part of multiple pituitary hormone deficiencies (MPHD) in most of the cases."
    explanation: >-
      This supports modeling a frequent MPHD-related mechanism alongside
      isolated monogenic central congenital hypothyroidism.
  - reference: PMID:39913280
    reference_title: "Newborn screening for central congenital hypothyroidism: past, present and future."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MPHD at birth, also known as 'congenital hypopituitarism', is a potentially life-threatening condition due to the possible co-occurrence of adrenocorticotropin hormone and growth hormone deficiency that can result in severe hypoglycemia and adrenal crisis."
    explanation: >-
      This gives the clinical consequence of coexisting ACTH and GH deficiency
      in congenital hypopituitarism.
phenotypes:
- category: Biochemical
  name: Low Free Thyroxine With Non-Elevated TSH
  description: >-
    The diagnostic biochemical pattern is low free thyroxine with TSH that is
    low, normal, or only mildly elevated for the degree of hypothyroxinemia.
  diagnostic: true
  evidence:
  - reference: PMID:39913280
    reference_title: "Newborn screening for central congenital hypothyroidism: past, present and future."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Central CH is caused by insufficient pituitary or hypothalamic control of thyroid function, biochemically characterized by a low serum free thyroxine (fT4), in combination with a low, normal or mildly elevated thyroid-stimulating hormone (TSH)."
    explanation: >-
      The abstract states the biochemical pattern used to recognize central
      congenital hypothyroidism.
- category: Clinical
  name: Congenital Hypothyroidism
  description: >-
    Thyroid hormone deficiency is present at birth, but symptoms can be subtle
    or missed if newborn screening relies only on TSH.
  phenotype_term:
    preferred_term: Congenital hypothyroidism
    term:
      id: HP:0000851
      label: Congenital hypothyroidism
  diagnostic: true
  evidence:
  - reference: PMID:39913280
    reference_title: "Newborn screening for central congenital hypothyroidism: past, present and future."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Congenital hypothyroidism (CH) is defined as thyroid hormone deficiency at birth and constitutes one of the most common causes of preventable intellectual disability worldwide."
    explanation: >-
      This supports the congenital hypothyroidism phenotype and the rationale
      for early detection.
- category: Clinical
  name: Neonatal Hypoglycemia
  description: >-
    Hypoglycemia can occur in affected neonates, especially when central
    congenital hypothyroidism is part of combined pituitary hormone deficiency.
  phenotype_term:
    preferred_term: Neonatal hypoglycemia
    term:
      id: HP:0001998
      label: Neonatal hypoglycemia
  evidence:
  - reference: PMID:42048107
    reference_title: "Retrospective, multicentre evaluation of central congenital hypothyroidism in the UK."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Non-specific neonatal concerns (hypoglycaemia/jaundice/weight concerns, 83%) and significant neurodevelopmental defects (34%) occurred frequently."
    explanation: >-
      The UK cohort reports hypoglycemia among frequent nonspecific neonatal
      concerns in clinically diagnosed cases.
- category: Clinical
  name: Prolonged Neonatal Jaundice
  description: >-
    Jaundice is one of the nonspecific neonatal presentations that can accompany
    delayed recognition of central congenital hypothyroidism.
  phenotype_term:
    preferred_term: Neonatal jaundice
    term:
      id: HP:0006579
      label: Prolonged neonatal jaundice
  evidence:
  - reference: PMID:42048107
    reference_title: "Retrospective, multicentre evaluation of central congenital hypothyroidism in the UK."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Non-specific neonatal concerns (hypoglycaemia/jaundice/weight concerns, 83%) and significant neurodevelopmental defects (34%) occurred frequently."
    explanation: >-
      The cohort explicitly includes jaundice among frequent nonspecific
      neonatal concerns.
- category: Clinical
  name: Neurodevelopmental Abnormality
  description: >-
    Delayed detection and treatment can be associated with neurodevelopmental
    morbidity, reflecting the developmental importance of early thyroid hormone
    sufficiency.
  phenotype_term:
    preferred_term: Neurodevelopmental abnormality
    term:
      id: HP:0012759
      label: Neurodevelopmental abnormality
  evidence:
  - reference: PMID:42048107
    reference_title: "Retrospective, multicentre evaluation of central congenital hypothyroidism in the UK."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Non-specific neonatal concerns (hypoglycaemia/jaundice/weight concerns, 83%) and significant neurodevelopmental defects (34%) occurred frequently."
    explanation: >-
      This cohort directly reports neurodevelopmental defects in a substantial
      fraction of clinically diagnosed cases.
- category: Clinical
  name: Obesity
  description: >-
    Obesity is reported in a subset of isolated central congenital
    hypothyroidism cases, particularly among patients with IGSF1 variants.
  phenotype_term:
    preferred_term: Obesity
    term:
      id: HP:0001513
      label: Obesity
  evidence:
  - reference: PMID:38462462
    reference_title: Clinical and molecular analyses of isolated central congenital hypothyroidism based on a survey conducted in Japan.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "One and two patients with IGSF1 variant had obesity and intellectual disability, respectively."
    explanation: >-
      This supports obesity as an associated phenotype in IGSF1-related
      isolated central congenital hypothyroidism.
- category: Clinical
  name: Pituitary Hypoplasia
  description: >-
    Pituitary hypoplasia has been reported in both variant-positive and
    variant-negative isolated central congenital hypothyroidism.
  phenotype_term:
    preferred_term: Anterior pituitary hypoplasia
    term:
      id: HP:0010627
      label: Anterior pituitary hypoplasia
  evidence:
  - reference: PMID:38462462
    reference_title: Clinical and molecular analyses of isolated central congenital hypothyroidism based on a survey conducted in Japan.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Two of the four variant-negative patients and a variant-positive patient were diagnosed with pituitary hypoplasia."
    explanation: >-
      This directly reports pituitary hypoplasia in the Japanese isolated
      central congenital hypothyroidism survey.
- category: Clinical
  name: Short Stature Or Reduced Growth Rate In IGSF1 Deficiency
  description: >-
    IGSF1-related central congenital hypothyroidism can be recognized later in
    childhood because of reduced growth rate or short stature.
  phenotype_term:
    preferred_term: Short stature
    term:
      id: HP:0004322
      label: Short stature
  evidence:
  - reference: PMID:38299175
    reference_title: A novel variant of IGSF1 in siblings with congenital central hypothyroidism whose diagnosis was prompted by school health checkups.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "School checkups revealed that the older brother was overweight and had a reduced growth rate at the age of 11 yr, whereas the younger brother was overweight and had short stature at the age of 8 yr."
    explanation: >-
      This sibling case report directly supports growth failure and short
      stature as features prompting diagnosis in IGSF1 deficiency.
- category: Clinical
  name: Reduced Circulating Prolactin Concentration
  description: >-
    Prolactin deficiency can accompany IGSF1-related central congenital
    hypothyroidism.
  phenotype_term:
    preferred_term: Prolactin deficiency
    term:
      id: HP:0008202
      label: Reduced circulating prolactin concentration
  evidence:
  - reference: PMID:38299175
    reference_title: A novel variant of IGSF1 in siblings with congenital central hypothyroidism whose diagnosis was prompted by school health checkups.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Only the older brother had prolactin deficiency and testicular growth without elevated testosterone levels."
    explanation: >-
      This directly supports prolactin deficiency in one affected sibling with
      IGSF1 deficiency.
- category: Clinical
  name: Macroorchidism Or Testicular Enlargement
  description: >-
    Dissociated testicular growth without parallel testosterone elevation is a
    reported IGSF1-related feature and maps conservatively to macroorchidism.
  phenotype_term:
    preferred_term: Macroorchidism
    term:
      id: HP:0000053
      label: Macroorchidism
  evidence:
  - reference: PMID:38299175
    reference_title: A novel variant of IGSF1 in siblings with congenital central hypothyroidism whose diagnosis was prompted by school health checkups.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Only the older brother had prolactin deficiency and testicular growth without elevated testosterone levels."
    explanation: >-
      This supports testicular enlargement as an IGSF1-related associated
      feature; the HPO term is the closest phenotype-level mapping.
biochemical:
- name: Low Free Thyroxine
  presence: Present
  context: Diagnostic thyroid function testing
  notes: >-
    Low free thyroxine with non-elevated or only mildly elevated TSH is the core
    diagnostic biochemical abnormality.
  evidence:
  - reference: PMID:39913280
    reference_title: "Newborn screening for central congenital hypothyroidism: past, present and future."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Central CH is caused by insufficient pituitary or hypothalamic control of thyroid function, biochemically characterized by a low serum free thyroxine (fT4), in combination with a low, normal or mildly elevated thyroid-stimulating hormone (TSH)."
    explanation: >-
      This exact abstract sentence states the free-thyroxine abnormality and the
      inappropriately non-elevated TSH pattern.
- name: Normal, Low, Or Mildly Elevated TSH
  presence: Present
  context: Diagnostic thyroid function testing
  notes: >-
    TSH is unreliable as a sole screening or treatment-monitoring marker in
    central congenital hypothyroidism.
  evidence:
  - reference: PMID:37326450
    reference_title: "Neonatal screening for primary and central congenital hypothyroidism: is it time to go Dutch?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Most newborn screening (NBS) programs for CH are primarily TSH based and thereby do not detect central CH."
    explanation: >-
      This supports the diagnostic limitation of TSH-based screening in central
      congenital hypothyroidism.
genetic:
- name: Established isolated central congenital hypothyroidism genes
  relationship_type: CAUSATIVE
  presence: Present
  gene_term:
    preferred_term: IGSF1
    term:
      id: hgnc:5948
      label: IGSF1
  notes: >-
    Falcon summarized five established isolated central congenital
    hypothyroidism genes: TSHB, TRHR, IGSF1, TBL1X, and IRS4. The YAML anchors
    this genetic section on IGSF1 because the abstract evidence in the selected
    survey most directly supports IGSF1 as the most frequent identified gene in
    the Japanese isolated central congenital hypothyroidism cohort.
  variants:
  - name: IGSF1 NM_001555.5:c.3056G>A (p.Trp1019Ter)
    description: >-
      Novel nonsense variant reported in two siblings with congenital central
      hypothyroidism, overweight or growth abnormalities, and biochemical low
      free thyroxine with normal TSH.
    gene:
      preferred_term: IGSF1
      term:
        id: hgnc:5948
        label: IGSF1
    evidence:
    - reference: PMID:38299175
      reference_title: A novel variant of IGSF1 in siblings with congenital central hypothyroidism whose diagnosis was prompted by school health checkups.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The siblings harbored a novel nonsense variant in exon 16 of IGSF1 (NM_001555.5: c.3056G>A: p.Trp1019Ter) and were diagnosed with IGSF1 deficiency."
      explanation: >-
        This exact abstract sentence identifies the reported nonsense variant
        and its IGSF1 deficiency diagnosis.
  evidence:
  - reference: PMID:38462462
    reference_title: Clinical and molecular analyses of isolated central congenital hypothyroidism based on a survey conducted in Japan.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The results revealed IGSF1 and TBL1X pathogenic variants in nine and one patient, respectively."
    explanation: >-
      This supports pathogenic variants in IGSF1 and TBL1X among isolated
      central congenital hypothyroidism patients.
  - reference: PMID:38462462
    reference_title: Clinical and molecular analyses of isolated central congenital hypothyroidism based on a survey conducted in Japan.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The study revalidated that IGSF1 variants comprise the most frequent pathogenic variant in patients with isolated central CH in Japan."
    explanation: >-
      This supports IGSF1 as the leading identified genetic cause in that
      Japanese isolated central congenital hypothyroidism cohort.
  - reference: PMID:38299175
    reference_title: A novel variant of IGSF1 in siblings with congenital central hypothyroidism whose diagnosis was prompted by school health checkups.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The siblings harbored a novel nonsense variant in exon 16 of IGSF1 (NM_001555.5: c.3056G>A: p.Trp1019Ter) and were diagnosed with IGSF1 deficiency."
    explanation: >-
      This provides a concrete pathogenic IGSF1 variant example in sibling
      cases.
- name: TSHB pathogenic variants
  relationship_type: CAUSATIVE
  presence: Present
  gene_term:
    preferred_term: TSHB
    term:
      id: hgnc:12372
      label: TSHB
  inheritance:
  - name: Autosomal recessive
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
    evidence:
    - reference: PMID:28515030
      reference_title: Congenital Central Hypothyroidism Caused by a Novel Thyroid-Stimulating Hormone-Beta Subunit Gene Mutation in Two Siblings.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Both patients were homozygous and the parents were heterozygous."
      explanation: >-
        Homozygous affected siblings with heterozygous parents support
        autosomal recessive inheritance.
  evidence:
  - reference: PMID:28515030
    reference_title: Congenital Central Hypothyroidism Caused by a Novel Thyroid-Stimulating Hormone-Beta Subunit Gene Mutation in Two Siblings.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "However, mutations of the thyrotropin-releasing hormone receptor or thyroid-stimulating hormone-beta (TSHB) gene are responsible for isolated CCH."
    explanation: >-
      This abstract directly identifies TSHB mutations as a cause of isolated
      central congenital hypothyroidism.
- name: TRHR pathogenic variants
  relationship_type: CAUSATIVE
  presence: Present
  gene_term:
    preferred_term: TRHR
    term:
      id: hgnc:12299
      label: TRHR
  inheritance:
  - name: Autosomal recessive
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
    evidence:
    - reference: PMID:28419241
      reference_title: Central Hypothyroidism Due to a TRHR Mutation Causing Impaired Ligand Affinity and Transactivation of Gq.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Thyrotropin-releasing hormone (TRH) receptor (TRHR) defects are rare recessive disorders usually associated with incidentally identified CCH and short stature in childhood."
      explanation: >-
        This directly classifies TRHR defects as rare recessive disorders
        associated with central congenital hypothyroidism.
  evidence:
  - reference: PMID:28419241
    reference_title: Central Hypothyroidism Due to a TRHR Mutation Causing Impaired Ligand Affinity and Transactivation of Gq.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "CONTEXT: Central congenital hypothyroidism (CCH) is an underdiagnosed disorder characterized by deficient production and bioactivity of thyroid-stimulating hormone (TSH) leading to low thyroid hormone synthesis."
    explanation: >-
      This establishes the central congenital hypothyroidism context for the
      TRHR mutation study.
  - reference: PMID:28419241
    reference_title: Central Hypothyroidism Due to a TRHR Mutation Causing Impaired Ligand Affinity and Transactivation of Gq.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A unique missense TRHR defect identified in a consanguineous family is associated with central hypothyroidism in homozygotes and hyperthyrotropinemia in heterozygotes, suggesting compensatory elevation of TSH with reduced biopotency."
    explanation: >-
      This directly supports TRHR pathogenic variation causing central
      hypothyroidism in homozygotes.
diagnosis:
- name: Serum FT4 and TSH testing
  description: >-
    Diagnostic evaluation centers on serum free thyroxine and TSH, recognizing
    that TSH may be normal, low, or only mildly elevated despite low FT4.
  evidence:
  - reference: PMID:39913280
    reference_title: "Newborn screening for central congenital hypothyroidism: past, present and future."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Central CH is caused by insufficient pituitary or hypothalamic control of thyroid function, biochemically characterized by a low serum free thyroxine (fT4), in combination with a low, normal or mildly elevated thyroid-stimulating hormone (TSH)."
    explanation: >-
      This exact sentence states the diagnostic thyroid-function pattern.
- name: Central-sensitive newborn screening
  description: >-
    Newborn screening strategies that include T4 with reflex TSH and/or TBG can
    detect central congenital hypothyroidism, whereas TSH-only screening can
    miss it.
  evidence:
  - reference: PMID:37326450
    reference_title: "Neonatal screening for primary and central congenital hypothyroidism: is it time to go Dutch?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In the Netherlands, we have a unique T4-TSH-thyroxine-binding globulin (TBG) NBS algorithm for CH, which enables the detection of primary and central CH."
    explanation: >-
      This supports T4-TSH-TBG newborn screening as an implemented approach
      capable of detecting central congenital hypothyroidism.
  - reference: PMID:38462462
    reference_title: Clinical and molecular analyses of isolated central congenital hypothyroidism based on a survey conducted in Japan.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Unlike primary CH, central CH cannot be detected by newborn screening (NBS) using dry filter paper blood TSH levels, and early diagnosis remains challenging."
    explanation: >-
      This supports why TSH-only newborn screening misses central congenital
      hypothyroidism.
- name: Pituitary hormone evaluation
  description: >-
    Because central congenital hypothyroidism frequently occurs with multiple
    pituitary hormone deficiencies, evaluation for ACTH and growth hormone
    deficiency is clinically important.
  evidence:
  - reference: PMID:39913280
    reference_title: "Newborn screening for central congenital hypothyroidism: past, present and future."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MPHD at birth, also known as 'congenital hypopituitarism', is a potentially life-threatening condition due to the possible co-occurrence of adrenocorticotropin hormone and growth hormone deficiency that can result in severe hypoglycemia and adrenal crisis."
    explanation: >-
      This supports assessing other pituitary axes when central congenital
      hypothyroidism is suspected.
treatments:
- name: Levothyroxine Replacement
  description: >-
    Thyroid hormone replacement is the core treatment after diagnosis. In
    possible MPHD, clinicians must also consider adrenal insufficiency before or
    during thyroid hormone replacement.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: levothyroxine
      term:
        id: CHEBI:6446
        label: levothyroxine sodium anhydrous
  target_phenotypes:
  - preferred_term: Congenital hypothyroidism
    term:
      id: HP:0000851
      label: Congenital hypothyroidism
  target_mechanisms:
  - target: Reduced Thyroid Hormone Generation
    treatment_effect: MODULATES
    description: >-
      Levothyroxine replacement bypasses deficient endogenous thyroid hormone
      generation by supplying thyroid hormone pharmacologically.
    evidence:
    - reference: PMID:36761493
      reference_title: Guidelines for Newborn Screening of Congenital Hypothyroidism (2021 Revision).
      supports: PARTIAL
      evidence_source: HUMAN_CLINICAL
      snippet: "Newborn screening (NBS) for congenital hypothyroidism (CH) was started in 1979 in Japan, and early diagnosis and treatment improved the intelligence prognosis of CH patients."
      explanation: >-
        This supports early treatment benefit for congenital hypothyroidism
        generally, while the specific levothyroxine mechanism is standard
        endocrine inference from thyroid hormone replacement.
  evidence:
  - reference: PMID:36761493
    reference_title: Guidelines for Newborn Screening of Congenital Hypothyroidism (2021 Revision).
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Newborn screening (NBS) for congenital hypothyroidism (CH) was started in 1979 in Japan, and early diagnosis and treatment improved the intelligence prognosis of CH patients."
    explanation: >-
      This guideline abstract supports early treatment for congenital
      hypothyroidism generally; the specific levothyroxine management details
      are inferred from standard endocrine care rather than directly stated in
      the abstract.
- name: Central Congenital Hypothyroidism-Capable Newborn Screening
  description: >-
    T4-inclusive newborn screening with reflex TSH and TBG is a secondary
    prevention strategy that can detect central congenital hypothyroidism early.
  treatment_term:
    preferred_term: disease screening
    term:
      id: MAXO:0000124
      label: disease screening
  target_phenotypes:
  - preferred_term: Congenital hypothyroidism
    term:
      id: HP:0000851
      label: Congenital hypothyroidism
  evidence:
  - reference: PMID:39913280
    reference_title: "Newborn screening for central congenital hypothyroidism: past, present and future."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "To date, central CH is the only pituitary hormone deficiency suitable for newborn screening (NBS), providing an opportunity for early detection of MPHD."
    explanation: >-
      This supports newborn screening as a clinically relevant detection
      strategy for central congenital hypothyroidism and associated MPHD.
  - reference: PMID:37326450
    reference_title: "Neonatal screening for primary and central congenital hypothyroidism: is it time to go Dutch?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In the Netherlands, we have a unique T4-TSH-thyroxine-binding globulin (TBG) NBS algorithm for CH, which enables the detection of primary and central CH."
    explanation: >-
      This supports a concrete T4-TSH-TBG screening implementation.
datasets: []
notes: >-
  Curation was initiated with a minimal page before Falcon research, then
  expanded from the Falcon report and locally cached references. Treatment dose
  details from guideline full text were not quoted because DISMECH snippet
  validation checks the cached abstract text.

📚

References & Deep Research

Deep Research

1

Falcon ▸

Disease Characteristics Research Template

Edison Scientific Literature 29 citations 2026-05-10T11:21:10.662689

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

Disease Name: Central Congenital Hypothyroidism
MONDO ID: (if available)
Category: Mendelian

Research Objectives

Please provide a comprehensive research report on Central Congenital Hypothyroidism covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

What is the disease? Provide a concise overview.
What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
What are the common synonyms and alternative names?
Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
Risk Factors:

Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Genetic risk factors (causal variants, susceptibility loci, modifier genes)
Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
Protective Factors:

Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Genetic protective factors (protective variants, modifier alleles)
Environmental protective factors (diet, lifestyle, exposures that reduce risk)
Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Pathogenic Variants:
Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
Variant type/class (missense, frameshift, nonsense, splice-site, structural)
Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
Functional consequences (loss of function, gain of function, dominant negative)
Modifier Genes: Genes that modify disease severity or expression
Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

Search first: CDC databases, WHO, PubMed, NHANES
Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

Search first: PubMed, Gene Ontology, Reactome
Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Molecular Profiling (if available):
Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
Advanced Technologies (if applicable):
Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

Organ Level:
Primary organs directly affected
Secondary organ involvement (complications, secondary effects)
Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Tissue and Cell Level:
Specific tissue types affected (epithelial, connective, muscle, nervous)
Specific cell populations targeted (with Cell Ontology terms)

Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Subcellular Level:
Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Localization:
Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

Onset:
Typical age of onset (congenital, pediatric, adult, geriatric)
Onset pattern (acute, subacute, chronic, insidious)

Search first: OMIM, Orphanet, HPO, PubMed
Progression:
Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
Progression rate (rapid, slow, variable)
Disease course pattern (episodic, relapsing-remitting, progressive, stable)
Disease duration (self-limited, chronic lifelong)

Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Patterns:
Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

Epidemiology:
Prevalence (cases per 100,000 at given time)
Incidence (new cases per 100,000 per year)

Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
For Genetic Etiology:
Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
Population Demographics:
Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
Geographic distribution of specific variants
Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

Clinical Tests:
Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
Genetic Testing:

Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
Overview of recommended genetic testing approach
Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
FISH > Search first: ClinVar, cytogenetics databases, PubMed
Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
Omics-Based Diagnostics (if applicable):
RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
Clinical Criteria:
Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
Screening:
Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

Survival and Mortality:
Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
Morbidity and Function:
Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
Disease Course:
Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
Prediction:
Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

Pharmacotherapy:
Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
Advanced Therapeutics:
Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
Surgical and Interventional:
Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
Supportive and Rehabilitative:
Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
Experimental:
Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
Treatment Outcomes:
Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
Treatment Strategy:
Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

Prevention Levels:
Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
Immunization: Vaccine strategies (if applicable)

Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Screening and Early Detection:
Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
Behavioral Interventions: Lifestyle modifications to reduce risk

Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Counseling: Genetic counseling (risk assessment, family planning guidance)

Search first: NSGC resources, ACMG guidelines, GeneReviews
Public Health:
Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
Prophylaxis: Preventive medications or procedures

Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

Taxonomy: Species affected (with NCBI Taxon identifiers)

Search first: NCBI Taxonomy
Breed: Specific breeds affected (with VBO identifiers if applicable)

Search first: VBO (Vertebrate Breed Ontology)
Gene: Orthologous genes in other species (with NCBI Gene IDs)

Search first: NCBI Gene
Natural Disease:
Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
Comparative Biology:
Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
Transmission (if applicable):
Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

Model Types:
Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
Genetic Models:
Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
Model Characteristics:
Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
Applications:
Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
Resources:
Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

Cite primary literature (PMID preferred) for all mechanistic and clinical claims
Prioritize recent reviews and landmark papers
Include direct quotes from abstracts where possible to support key statements
Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Central Congenital Hypothyroidism (CCH) — Comprehensive Research Report

1. Disease information

Overview / definition. Central congenital hypothyroidism (CCH; also written “central CH”) is thyroid hormone deficiency present at birth due to insufficient hypothalamic and/or pituitary stimulation of an otherwise normal thyroid gland. It is biochemically characterized by low serum free thyroxine (FT4) with a low, normal, or mildly elevated thyroid-stimulating hormone (TSH) (“inappropriately” non-elevated for the degree of hypothyroxinemia). (garrelfs2025newbornscreeningfor pages 1-2, peters2026retrospectivemulticentreevaluation pages 14-17)

Key identifiers (knowledgebase note). This run did not retrieve OMIM/Orphanet/MONDO identifier records directly (no OMIM/Orphanet/MONDO pages were ingested), so these identifiers cannot be asserted from tool-evidence. Disease characterization below is derived from aggregated literature resources (guidelines/reviews) and patient-level clinical cohorts/case reports. (nagasaki2023guidelinesfornewborn pages 25-26, garrelfs2025newbornscreeningfor pages 1-2, peters2026retrospectivemulticentreevaluation pages 1-4, shibata2024clinicalandmolecular pages 1-2, yamamura2024anovelvariant pages 7-12)

Common synonyms. “Central CH”, “central congenital hypothyroidism”, “congenital central hypothyroidism”, and in some papers “CeCHT/CeCH” or “C-CH”. (garrelfs2025newbornscreeningfor pages 1-2, peters2026retrospectivemulticentreevaluation pages 1-4, yamamura2024anovelvariant pages 7-12)

Direct abstract quote (definition). Garrelfs et al. (European Thyroid Journal; 2025-02-01; https://doi.org/10.1530/etj-24-0329) states: “Central CH is caused by insufficient pituitary or hypothalamic control of thyroid function, biochemically characterized by a low serum free thyroxine (fT4), in combination with a low, normal or mildly elevated thyroid-stimulating hormone (TSH).” (garrelfs2025newbornscreeningfor pages 1-2)

2. Etiology

2.1 Disease causal factors

Genetic (Mendelian) causes—isolated CCH. A 2025 focused review states that isolated CCH is commonly monogenic, with five established genes: TSHB, TRHR, IGSF1, TBL1X, IRS4. (garrelfs2025newbornscreeningfor pages 2-4, garrelfs2025newbornscreeningfor pages 1-2)

Secondary/physiologic causes—transient central hypothyroidism. The same review notes that maternal thyrotoxicosis can lead to transient central CH due to in utero suppression of the fetal hypothalamic–pituitary–thyroid (HPT) axis. (garrelfs2025newbornscreeningfor pages 2-4)

2.2 Risk factors

Clinical risk context for missed/delayed diagnosis. In a UK multicentre cohort of clinically diagnosed cases (1996–2022), CCH often presented with non-specific neonatal concerns (hypoglycaemia, jaundice, weight concerns) and diagnostic uncertainty due to reference-range issues and confounders (e.g., prematurity, non-thyroidal illness). (peters2026retrospectivemulticentreevaluation pages 1-4, peters2026retrospectivemulticentreevaluation pages 14-17)

Inheritance risk. Several isolated CCH causes are X-linked (IGSF1, TBL1X, IRS4), so male sex and family history can be relevant in those families. (garrelfs2025newbornscreeningfor pages 2-4, shibata2024clinicalandmolecular pages 2-4)

2.3 Protective factors / gene–environment interactions

No specific protective factors or gene–environment interactions were retrieved in the present evidence corpus.

3. Phenotypes (clinical presentation)

3.1 Core laboratory phenotype (diagnostic pattern)

Low FT4 with inappropriately low/normal TSH; T3 may be normal. (garrelfs2025newbornscreeningfor pages 1-2, peters2026retrospectivemulticentreevaluation pages 14-17)

Ontology suggestions (laboratory): - HPO: Low circulating free thyroxine concentration (e.g., “Low free T4”); Inappropriately normal TSH / Low TSH (use appropriate HPO terms depending on case). - LOINC examples (test concepts): FT4, TSH, FT3; also TBG when screening algorithms require it. (nagasaki2023guidelinesfornewborn pages 25-26)

3.2 Clinical phenotypes and frequencies (selected evidence)

CCH with multiple pituitary hormone deficiency (MPHD/CPHD). CCH is frequently part of MPHD (“congenital hypopituitarism”) and may be life-threatening due to coexisting ACTH and GH deficiency. Reviews cite additional pituitary deficiencies in 61–98% of CCH cases. (garrelfs2025newbornscreeningfor pages 1-2)

UK clinically detected cohort (n=118). - Median age at diagnosis: 68 days (range 1–5056). (peters2026retrospectivemulticentreevaluation pages 1-4) - 96% had combined pituitary hormone deficiencies. (peters2026retrospectivemulticentreevaluation pages 1-4) - Non-specific neonatal concerns occurred in 83% (hypoglycaemia/jaundice/weight concerns). (peters2026retrospectivemulticentreevaluation pages 1-4) - Neurodevelopmental defects were reported in 34%. (peters2026retrospectivemulticentreevaluation pages 1-4)

Isolated CCH—Japan survey (isolated n=14). - Genotype-associated patterns: median diagnosis age 1–2 months for IGSF1/TBL1X vs 14 months for variant-negative. (shibata2024clinicalandmolecular pages 2-4) - Reported associated findings include obesity, intellectual disability, and pituitary hypoplasia in subsets. (shibata2024clinicalandmolecular pages 1-2, shibata2024clinicalandmolecular pages 4-6)

Isolated CCH—IGSF1 siblings case report (Japan). Two brothers were diagnosed later in childhood after school growth monitoring, with a novel nonsense variant IGSF1 NM_001555.5:c.3056G>A (p.Trp1019Ter) and biochemical profile of low FT4 with normal TSH; additional features included overweight/obesity, dyslipidaemia (improved after levothyroxine), and in one brother prolactin deficiency with dissociated pubertal findings (testicular enlargement without testosterone rise). (yamamura2024anovelvariant pages 7-12)

Ontology suggestions (selected): - HPO: Congenital hypothyroidism, Hypothyroxinemia, Hypoglycemia, Neonatal jaundice, Failure to thrive / Poor weight gain (or weight concerns), Obesity, Intellectual disability, Short stature / Decreased growth rate, Prolactin deficiency, Macroorchidism. (peters2026retrospectivemulticentreevaluation pages 1-4, shibata2024clinicalandmolecular pages 1-2, yamamura2024anovelvariant pages 7-12)

4. Genetic / molecular information

4.1 Causal genes (isolated CCH)

Established genes. Reviews identify TSHB, TRHR, IGSF1, TBL1X, IRS4 as established monogenic causes of isolated CCH. (garrelfs2025newbornscreeningfor pages 1-2, garrelfs2025newbornscreeningfor pages 2-4)

Inheritance notes (from review/guidelines context). IGSF1, TBL1X, and IRS4 are described as X-linked causes; TSHB and TRHR are rare causes and are commonly considered autosomal recessive in clinical genetics practice (inheritance mode not explicitly enumerated in all retrieved snippets). (garrelfs2025newbornscreeningfor pages 2-4, boelen2023neonatalscreeningfor pages 2-4)

4.2 Pathogenic variants (examples from 2024 literature)

IGSF1: nonsense variant NM_001555.5:c.3056G>A (p.Trp1019Ter) in two affected brothers; reported as absent from population databases and predicted loss-of-function, consistent with ACMG PVS1/PM1/PP1. (yamamura2024anovelvariant pages 7-12)

4.3 Gene frequencies in recent cohorts

Japan survey: among 14 isolated CCH patients, sequencing across known genes found IGSF1 variants in 9 and TBL1X variant in 1; remaining 4 were variant-negative. (shibata2024clinicalandmolecular pages 2-4)

Direct abstract quote (gene frequency). Shibata et al. (Endocrine Journal; 2024-03-01; https://doi.org/10.1507/endocrj.ej23-0391) concludes: “The study revalidated that IGSF1 variants comprise the most frequent pathogenic variant in patients with isolated central CH in Japan.” (shibata2024clinicalandmolecular pages 1-2)

5. Environmental information

No consistent non-genetic environmental causes beyond maternal thyroid status–related transient cases were retrieved here. Maternal thyrotoxicosis-related fetal axis suppression is highlighted as a transient cause. (garrelfs2025newbornscreeningfor pages 2-4)

6. Mechanism / pathophysiology

6.1 Causal chain (high-level)

1) Upstream defect: impaired hypothalamic TRH signaling or pituitary thyrotrope function (genetic defects in TSHB/TRHR/IGSF1/TBL1X/IRS4; or transient fetal suppression from maternal thyrotoxicosis). (garrelfs2025newbornscreeningfor pages 2-4, garrelfs2025newbornscreeningfor pages 1-2) 2) Hormone output: insufficient/ineffective TSH drive → reduced thyroid hormone secretion → low FT4 with non-elevated TSH. (garrelfs2025newbornscreeningfor pages 1-2, peters2026retrospectivemulticentreevaluation pages 14-17) 3) Downstream outcomes: thyroid hormone deficiency in a critical developmental window contributes to neurodevelopmental risk; in MPHD, concurrent ACTH/GH deficiencies can add risk through hypoglycaemia and adrenal crisis that levothyroxine alone cannot prevent. (garrelfs2025newbornscreeningfor pages 1-2, garrelfs2025newbornscreeningfor pages 2-4)

6.2 Cell types and processes (ontology suggestions)

Cell Ontology (CL): pituitary thyrotroph (TSH-producing cell), hypothalamic TRH neuron, pituitary corticotroph (ACTH) and somatotroph (GH) for MPHD context.
GO biological processes (suggested): hypothalamus–pituitary–thyroid axis development/regulation; regulation of hormone secretion; thyroid hormone mediated signaling pathway; neurodevelopmental processes influenced by thyroid hormone.

7. Anatomical structures affected

Primary axis: hypothalamus and pituitary regulation of thyroid function (HPT axis). (garrelfs2025newbornscreeningfor pages 1-2)
Secondary/complication-related systems: brain/neurodevelopmental outcomes; risk driven both by hypothyroxinemia and by hypoglycaemia/adrenal crisis in MPHD. (garrelfs2025newbornscreeningfor pages 1-2, peters2026retrospectivemulticentreevaluation pages 1-4)

UBERON suggestions: hypothalamus; pituitary gland (anterior pituitary); thyroid gland.

8. Temporal development

Onset: congenital (present at birth). (garrelfs2025newbornscreeningfor pages 1-2)
Diagnosis timing varies by screening strategy: screening-capable programs can identify within the first weeks; clinically diagnosed cohorts may be delayed (median 68 days in a UK cohort, with long tail to years). (peters2026retrospectivemulticentreevaluation pages 1-4)

9. Inheritance and population

9.1 Epidemiology

Incidence. Reviews/guidelines estimate incidence around ~1:13,000–1:30,000 live births, with country reports around 1:13,000–16,000 in settings using screening strategies that can detect CCH. (garrelfs2025newbornscreeningfor pages 1-2, nagasaki2023guidelinesfornewborn pages 25-26, olivieri2025isittime pages 4-5)

Direct abstract quote (incidence). Peters et al. (European Thyroid Journal; 2026-04-01; https://doi.org/10.1530/etj-26-0014) notes: “Central congenital hypothyroidism (incidence ∼1:13,000) occurs in isolation (40% cases) or with additional pituitary hormone deficiencies.” (peters2026retrospectivemulticentreevaluation pages 1-4)

9.2 Inheritance

X-linked: IGSF1, TBL1X, IRS4. (garrelfs2025newbornscreeningfor pages 2-4)
Other genetic forms: TSHB and TRHR are described as rare causes of isolated CCH in reviews; inheritance is commonly autosomal recessive in clinical genetics (not explicitly stated in all retrieved text). (boelen2023neonatalscreeningfor pages 2-4, nagasaki2023guidelinesfornewborn pages 25-26)

10. Diagnostics

10.1 Clinical tests / biomarkers

Core: serum FT4 and TSH; consider FT3, and in screening contexts TBG to interpret low total T4 and reduce false positives. (garrelfs2025newbornscreeningfor pages 1-2, nagasaki2023guidelinesfornewborn pages 25-26)

Diagnostic challenge (expert analysis). UK experience highlights that FT4 may require separate ordering and that lack of pediatric age-specific FT4 reference ranges can cause misclassification; central CH may be masked by non-thyroidal illness, transient hypothyroxinaemia of prematurity, or later “unmasking” after GH therapy. (peters2026retrospectivemulticentreevaluation pages 14-17)

10.2 Pituitary evaluation (MPHD risk)

Recommended evaluations include pituitary hormone assessment (e.g., TRH/CRH stimulation tests) and pituitary MRI when possible, reflecting the frequent MPHD association. (nagasaki2023guidelinesfornewborn pages 25-26)

10.3 Screening (newborn screening; real-world implementations)

Why TSH-only screening misses CCH. Because TSH can be normal/non-elevated despite low FT4, TSH-only dried blood spot (DBS) newborn screening detects primary CH but misses many CCH cases. In the Japanese survey, eight patients had TSH-only NBS with normal results, whereas six detected by low FT4 on NBS all carried IGSF1 variants. (shibata2024clinicalandmolecular pages 2-4, shibata2024clinicalandmolecular pages 1-2)

Dutch stepwise T4–TSH–TBG algorithm. The Netherlands uses a stepwise total T4 → reflex TSH → reflex TBG newborn screening approach to detect both primary and central CH while mitigating false positives from TBG deficiency. A figure of this algorithm is available from Boelen et al. (2023-06-01; https://doi.org/10.1530/etj-23-0041). (boelen2023neonatalscreeningfor pages 2-4, boelen2023neonatalscreeningfor media e737b93b)

Machine-learning refinement (2023 development). A Dutch study (Jansen et al., European Thyroid Journal; 2023-10-01; https://doi.org/10.1530/etj-23-0141) trained a random-forest model using 1,079 false-positive referrals, 515 CH cases (431 primary; 84 central) and 1,842 controls; at enforced sensitivity 1.00, it achieved PPV 0.48 and AUROC 0.99, highlighting tyrosine and succinylacetone (among others) as additional informative analytes. (jansen2023optimizingthedutch pages 1-2, jansen2023optimizingthedutch pages 5-7)

11. Outcome / prognosis

Neurodevelopmental burden with delayed detection. A 2025 review summarizes multiple datasets reporting high rates of impairment when detection is late (e.g., developmental delay in 51% of 42 late-detected patients; neurologic sequelae in 37% of 94 patients; and higher sequelae in isolated CCH vs MPHD in one dataset). (garrelfs2025newbornscreeningfor pages 2-4)

UK cohort outcomes. In the 118-case UK cohort, 34% had neurodevelopmental defects and late-diagnosed cases experienced substantial treatment delays (mean delay 208 ± 486 days). (peters2026retrospectivemulticentreevaluation pages 1-4)

12. Treatment

12.1 Standard of care

Thyroid hormone replacement. Levothyroxine (L‑T4) is the core therapy; dosing targets should be based on FT4 because TSH is unreliable in CCH. (nagasaki2023guidelinesfornewborn pages 25-26)

Hydrocortisone-first precaution (MPHD context). Guidelines emphasize that hydrocortisone should be replaced before starting L‑T4 if ACTH deficiency is possible, because initiating L‑T4 can precipitate adrenal insufficiency; monitoring for adrenal insufficiency is advised, particularly around 7–10 days after starting L‑T4. (nagasaki2023guidelinesfornewborn pages 25-26)

Dose recommendations (guideline). For NBS-detected CCH, starting L‑T4 dose recommendations include 10–15 μg/kg/day for severe CCH (FT4 <0.4 ng/dL) and 5–10 μg/kg/day for moderate-to-severe CCH (FT4 0.4–1.2 ng/dL), aiming for FT4 in the average-to-upper age-specific reference range. (nagasaki2023guidelinesfornewborn pages 25-26)

MAXO suggestions: - Levothyroxine replacement therapy; adrenal hormone replacement (hydrocortisone) when indicated; newborn screening; pituitary MRI; endocrine function testing.

12.2 Clinical trials / experimental therapies

No CCH-specific interventional clinical trials were retrieved by the tools in this run.

13. Prevention

Secondary prevention is key: newborn screening strategies capable of detecting low T4/FT4 with non-elevated TSH, plus confirmatory testing and early initiation of therapy. (garrelfs2025newbornscreeningfor pages 1-2, olivieri2025isittime pages 2-4)

Expert opinion on screening expansion. A 2025 review notes European guideline support for adding TT4/FT4 to TSH for detecting central CH and recommends optimization (e.g., TBG measurement; repeat screens in preterm/sick neonates) to manage false positives and cost. (olivieri2025isittime pages 2-4)

14. Other species / natural disease

No naturally occurring veterinary analogs were retrieved in the present evidence corpus.

15. Model organisms

A 2024 study assessed Irs4 knockout mice and found the murine HPT axis remained intact under tested conditions, suggesting compensation and potential limitations of this model for human IRS4-related CCH. (garrelfs2025newbornscreeningfor pages 2-4)

Recent developments (prioritizing 2023–2024)

1) National/genotype-focused characterization (Japan, 2024). A Japanese survey revalidated IGSF1 as the most frequent known cause of isolated CCH and illustrated how FT4-inclusive screening strategies preferentially identify IGSF1 cases early. (shibata2024clinicalandmolecular pages 1-2, shibata2024clinicalandmolecular pages 2-4) 2) Real-world delayed detection pathway evidence (UK cohort; 2026, but provides contemporary system-level evidence). The UK multicentre cohort quantified delayed diagnosis and morbidity in TSH-only screening settings. (peters2026retrospectivemulticentreevaluation pages 1-4) 3) Screening-analytics innovation (Netherlands, 2023). Machine-learning use of amino acids/acylcarnitines improved modeled PPV for Dutch screening while preserving high sensitivity, suggesting feasible laboratory augmentations where these analytes are already measured for metabolic screening. (jansen2023optimizingthedutch pages 1-2, jansen2023optimizingthedutch pages 5-7)

Current applications and real-world implementations

Dutch national screening algorithm (T4–TSH–TBG) is an operational example that detects both primary and central CH using DBS measurements and TBG-based discrimination of binding-protein effects. (boelen2023neonatalscreeningfor pages 2-4, boelen2023neonatalscreeningfor media e737b93b)
Clinical pathway emphasis in TSH-only programs: need for clinician vigilance and FT4 measurement in symptomatic neonates/infants, given that TSH can be misleadingly normal in CCH. (peters2026retrospectivemulticentreevaluation pages 14-17)

Summary table (evidence synthesis)

Topic	Key findings	Main supporting citation context IDs
Definition / biochemical criteria	Central congenital hypothyroidism (CCH) is thyroid hormone deficiency present at birth due to insufficient hypothalamic and/or pituitary stimulation of the thyroid; the characteristic biochemical pattern is low serum free T4 (FT4) with a low, normal, or only mildly elevated TSH, so TSH is “inappropriately” non-elevated for the degree of hypothyroxinemia.	(garrelfs2025newbornscreeningfor pages 1-2, nagasaki2023guidelinesfornewborn pages 25-26, peters2026retrospectivemulticentreevaluation pages 14-17)
Estimated incidence	Recent reviews/guidelines place incidence at roughly 1:13,000–1:30,000 live births overall; country-specific estimates include ~1:13,000 in Japan/UK-centered discussions and ~1:16,404 in the Dutch screening program.	(garrelfs2025newbornscreeningfor pages 1-2, nagasaki2023guidelinesfornewborn pages 25-26, peters2026retrospectivemulticentreevaluation pages 1-4, olivieri2025isittime pages 4-5)
MPHD vs isolated disease	CCH is most often part of multiple pituitary hormone deficiency (MPHD/CPHD), with reported additional pituitary deficiencies in 61%–98% of cases; one review states about one-third are isolated, whereas a UK clinically ascertained cohort found 96% had additional pituitary hormone deficiencies and estimated isolated disease may account for ~40% overall in broader populations.	(garrelfs2025newbornscreeningfor pages 1-2, boelen2023neonatalscreeningfor pages 2-4, peters2026retrospectivemulticentreevaluation pages 1-4)
Established monogenic causes: overview	Five established genes for isolated monogenic CCH are TSHB, TRHR, IGSF1, TBL1X, and IRS4. TSHB and TRHR were recognized earlier as rare causes; IGSF1, TBL1X, and IRS4 were identified more recently and explain many isolated cases found by modern sequencing approaches.	(garrelfs2025newbornscreeningfor pages 2-4, garrelfs2025newbornscreeningfor pages 1-2, boelen2023neonatalscreeningfor pages 2-4, nagasaki2023guidelinesfornewborn pages 25-26)
TSHB	TSHB causes isolated central hypothyroidism/isolated TSH deficiency; inheritance is typically autosomal recessive. Clinically important because immunoreactive TSH can be low/normal or sometimes biologically weak despite measurable concentrations.	(nagasaki2023guidelinesfornewborn pages 25-26, boelen2023neonatalscreeningfor pages 2-4, peters2026retrospectivemulticentreevaluation pages 14-17)
TRHR	TRHR is an established but very rare cause of isolated CCH; inheritance is typically autosomal recessive. It disrupts hypothalamic TRH signaling to pituitary thyrotropes.	(garrelfs2025newbornscreeningfor pages 2-4, boelen2023neonatalscreeningfor pages 2-4, nagasaki2023guidelinesfornewborn pages 25-26)
IGSF1	IGSF1 is an X-linked cause and appears to be the most frequent known monogenic cause of isolated CCH in several series. Associated features can include obesity, macroorchidism/dissociated testicular enlargement, prolactin deficiency, and occasional intellectual disability. In the Japanese survey, 9/14 isolated cases carried IGSF1 variants; all 6 cases detected by low FT4 on NBS had IGSF1 variants.	(garrelfs2025newbornscreeningfor pages 2-4, boelen2023neonatalscreeningfor pages 2-4, shibata2024clinicalandmolecular pages 1-2, shibata2024clinicalandmolecular pages 2-4, yamamura2024anovelvariant pages 7-12)
TBL1X	TBL1X is an X-linked cause of isolated CCH, often associated with hearing-related or visual/neurodevelopmental findings in some reports. In the Japanese survey, 1/14 isolated cases carried a TBL1X variant; a TBL1X-related form has also been linked mechanistically to altered thyroid hormone action/gene regulation.	(garrelfs2025newbornscreeningfor pages 2-4, shibata2024clinicalandmolecular pages 1-2, shibata2024clinicalandmolecular pages 4-6)
IRS4	IRS4 is an X-linked cause of isolated CCH. Human patients show reduced TSH secretion, but a 2024 mouse knockout study did not reproduce central hypothyroidism, suggesting species differences or compensation by other IRS proteins.	(garrelfs2025newbornscreeningfor pages 2-4)
Why TSH-only screening misses CCH	Standard DBS TSH-only newborn screening misses many CCH cases because TSH is often normal or not appropriately elevated despite low FT4. In one Japanese survey, 8 patients had TSH-only NBS and normal results, whereas low FT4-based detection identified cases.	(garrelfs2025newbornscreeningfor pages 1-2, shibata2024clinicalandmolecular pages 1-2, shibata2024clinicalandmolecular pages 2-4, yamamura2024anovelvariant pages 7-12)
T4-based screening	Earlier T4-based newborn screening could detect both primary CH and CCH, but many programs moved away from it because of high false-positive rates and confounding from TBG deficiency, prematurity, and illness.	(garrelfs2025newbornscreeningfor pages 1-2, garrelfs2025newbornscreeningfor pages 2-4, peters2026retrospectivemulticentreevaluation pages 4-6)
Dutch T4–TSH–TBG algorithm	The Dutch program uses a stepwise T4–TSH–TBG algorithm: total T4 for all newborns, reflex TSH in low-T4 samples, and TBG to help distinguish true hypothyroxinemia from TBG deficiency. This approach detects both primary CH and CCH while improving specificity; reported PPV for the Dutch program over 2007–2017 was ~21%, and Dutch incidence of detected CCH was ~1:16,404.	(boelen2023neonatalscreeningfor pages 2-4, olivieri2025isittime pages 4-5, boelen2023neonatalscreeningfor media e737b93b)
Machine-learning enhancement of Dutch screening	A 2023 Dutch random-forest model incorporating amino acids and acylcarnitines used 1,079 false-positive referrals, 515 CH cases (431 primary, 84 central), and 1,842 controls. With artificial sensitivity of 100%, PPV improved from 26% in a prior ML model to 48%, with AUROC 0.99. Key added contributors included tyrosine and succinylacetone, alongside T4, TSH, TBG, and T4/TBG ratio.	(jansen2023optimizingthedutch pages 1-2, jansen2023optimizingthedutch pages 5-7, jansen2023optimizingthedutch pages 8-9)
Diagnostic timing / real-world detection	Without central-sensitive screening, diagnosis is often delayed by months to years. In a UK multicenter cohort, median age at diagnosis was 68 days (range 1–5056), despite many neonatal symptoms. In the Japanese survey, median age at diagnosis was 1–2 months in IGSF1/TBL1X-positive cases versus 14 months in variant-negative patients.	(peters2026retrospectivemulticentreevaluation pages 1-4, shibata2024clinicalandmolecular pages 2-4)
Selected prognosis / outcome statistics	Reported adverse neurodevelopmental outcomes remain substantial when diagnosis is delayed: developmental delay in 51% of 42 late-detected patients; neurologic sequelae in 37% of 94 patients; higher neurologic sequelae in isolated CCH vs MPHD (60% vs 32%) in one series. In the UK cohort, neurodevelopmental defects were reported in 34%, and treatment delays in late-diagnosed cases averaged 208 ± 486 days.	(garrelfs2025newbornscreeningfor pages 2-4, peters2026retrospectivemulticentreevaluation pages 1-4, peters2026retrospectivemulticentreevaluation pages 14-17)
Treatment / management implications	Because MPHD and ACTH deficiency may coexist, hydrocortisone should be given before levothyroxine when adrenal insufficiency is possible. Guideline-recommended starting levothyroxine doses are 10–15 µg/kg/day for severe CCH and 5–10 µg/kg/day for moderate CCH, targeting FT4 in the upper reference range because TSH is unreliable for titration.	(nagasaki2023guidelinesfornewborn pages 25-26, garrelfs2025newbornscreeningfor pages 1-2)

Table: This table summarizes central congenital hypothyroidism across definition, epidemiology, genetics, screening, and prognosis. It highlights why TSH-only screening misses cases and how Dutch T4–TSH–TBG and machine-learning approaches improve detection.

Key screening algorithm figure (Dutch strategy)

The following figure region summarizes the Dutch stepwise T4–TSH–TBG screening algorithm used to detect central CH in addition to primary CH. (boelen2023neonatalscreeningfor media e737b93b, boelen2023neonatalscreeningfor media 77a8ab01)

Evidence gaps / limitations of this run

Ontology identifiers (MONDO/Orphanet/OMIM/MeSH/ICD) were not retrieved in the tool evidence and therefore cannot be asserted here.
Evidence in this run is strong for definition, screening, and selected genetic etiologies (especially IGSF1), but less complete for rare gene-specific penetrance/expressivity, population-specific variant frequencies, and comprehensive non-genetic contributors.

References

(garrelfs2025newbornscreeningfor pages 1-2): Mark R Garrelfs, Christiaan F Mooij, Anita Boelen, A S Paul van Trotsenburg, and Nitash Zwaveling-Soonawala. Newborn screening for central congenital hypothyroidism: past, present and future. European Thyroid Journal, Feb 2025. URL: https://doi.org/10.1530/etj-24-0329, doi:10.1530/etj-24-0329. This article has 6 citations and is from a peer-reviewed journal.
(peters2026retrospectivemulticentreevaluation pages 14-17): Catherine Peters, Claire Wood, James M. Law, Chloe Stevens, Fatemah Alhusaini, Darla Rigby, Hannah Hornby, Tim Cheetham, and Nadia Schoenmakers. Retrospective, multicentre evaluation of central congenital hypothyroidism in the uk. European Thyroid Journal, Apr 2026. URL: https://doi.org/10.1530/etj-26-0014, doi:10.1530/etj-26-0014. This article has 0 citations and is from a peer-reviewed journal.
(nagasaki2023guidelinesfornewborn pages 25-26): Keisuke Nagasaki, Kanshi Minamitani, Akie Nakamura, Hironori Kobayashi, Chikahiko Numakura, Masatsune Itoh, Yuichi Mushimoto, Kaori Fujikura, Masaru Fukushi, and Toshihiro Tajima. Guidelines for newborn screening of congenital hypothyroidism (2021 revision). Clinical Pediatric Endocrinology, 32:26-51, Jan 2023. URL: https://doi.org/10.1297/cpe.2022-0063, doi:10.1297/cpe.2022-0063. This article has 33 citations and is from a peer-reviewed journal.
(peters2026retrospectivemulticentreevaluation pages 1-4): Catherine Peters, Claire Wood, James M. Law, Chloe Stevens, Fatemah Alhusaini, Darla Rigby, Hannah Hornby, Tim Cheetham, and Nadia Schoenmakers. Retrospective, multicentre evaluation of central congenital hypothyroidism in the uk. European Thyroid Journal, Apr 2026. URL: https://doi.org/10.1530/etj-26-0014, doi:10.1530/etj-26-0014. This article has 0 citations and is from a peer-reviewed journal.
(shibata2024clinicalandmolecular pages 1-2): Nao Shibata, Chikahiko Numakura, Takashi Hamajima, Kenichi Miyako, Ikuma Fujiwara, Jun Mori, Akihiko Saitoh, and Keisuke Nagasaki. Clinical and molecular analyses of isolated central congenital hypothyroidism based on a survey conducted in japan. Endocrine journal, 71:471-480, Mar 2024. URL: https://doi.org/10.1507/endocrj.ej23-0391, doi:10.1507/endocrj.ej23-0391. This article has 3 citations and is from a peer-reviewed journal.
(yamamura2024anovelvariant pages 7-12): Yoshiko Yamamura, Maki Fukami, Misayo Matsuyama, and Hirotake Sawada. A novel variant of <i>igsf1</i> in siblings with congenital central hypothyroidism whose diagnosis was prompted by school health checkups. Clinical Pediatric Endocrinology, 33:17-22, Jan 2024. URL: https://doi.org/10.1297/cpe.2023-0046, doi:10.1297/cpe.2023-0046. This article has 0 citations and is from a peer-reviewed journal.
(garrelfs2025newbornscreeningfor pages 2-4): Mark R Garrelfs, Christiaan F Mooij, Anita Boelen, A S Paul van Trotsenburg, and Nitash Zwaveling-Soonawala. Newborn screening for central congenital hypothyroidism: past, present and future. European Thyroid Journal, Feb 2025. URL: https://doi.org/10.1530/etj-24-0329, doi:10.1530/etj-24-0329. This article has 6 citations and is from a peer-reviewed journal.
(shibata2024clinicalandmolecular pages 2-4): Nao Shibata, Chikahiko Numakura, Takashi Hamajima, Kenichi Miyako, Ikuma Fujiwara, Jun Mori, Akihiko Saitoh, and Keisuke Nagasaki. Clinical and molecular analyses of isolated central congenital hypothyroidism based on a survey conducted in japan. Endocrine journal, 71:471-480, Mar 2024. URL: https://doi.org/10.1507/endocrj.ej23-0391, doi:10.1507/endocrj.ej23-0391. This article has 3 citations and is from a peer-reviewed journal.
(shibata2024clinicalandmolecular pages 4-6): Nao Shibata, Chikahiko Numakura, Takashi Hamajima, Kenichi Miyako, Ikuma Fujiwara, Jun Mori, Akihiko Saitoh, and Keisuke Nagasaki. Clinical and molecular analyses of isolated central congenital hypothyroidism based on a survey conducted in japan. Endocrine journal, 71:471-480, Mar 2024. URL: https://doi.org/10.1507/endocrj.ej23-0391, doi:10.1507/endocrj.ej23-0391. This article has 3 citations and is from a peer-reviewed journal.
(boelen2023neonatalscreeningfor pages 2-4): Anita Boelen, Nitash Zwaveling-Soonawala, Annemieke C Heijboer, and A S Paul van Trotsenburg. Neonatal screening for primary and central congenital hypothyroidism: is it time to go dutch? European Thyroid Journal, Jun 2023. URL: https://doi.org/10.1530/etj-23-0041, doi:10.1530/etj-23-0041. This article has 26 citations and is from a peer-reviewed journal.
(olivieri2025isittime pages 4-5): Antonella Olivieri, Maria Cristina Vigone, Mariacarolina Salerno, and Luca Persani. Is it time to expand newborn screening for congenital hypothyroidism to other rare thyroid diseases? International Journal of Neonatal Screening, 11:65, Aug 2025. URL: https://doi.org/10.3390/ijns11030065, doi:10.3390/ijns11030065. This article has 0 citations.
(boelen2023neonatalscreeningfor media e737b93b): Anita Boelen, Nitash Zwaveling-Soonawala, Annemieke C Heijboer, and A S Paul van Trotsenburg. Neonatal screening for primary and central congenital hypothyroidism: is it time to go dutch? European Thyroid Journal, Jun 2023. URL: https://doi.org/10.1530/etj-23-0041, doi:10.1530/etj-23-0041. This article has 26 citations and is from a peer-reviewed journal.
(jansen2023optimizingthedutch pages 1-2): Heleen I Jansen, Marije van Haeringen, Marelle J Bouva, Wendy P J den Elzen, Eveline Bruinstroop, Catharina P B van der Ploeg, A S Paul van Trotsenburg, Nitash Zwaveling-Soonawala, Annemieke C Heijboer, Annet M Bosch, Robert de Jonge, Mark Hoogendoorn, and Anita Boelen. Optimizing the dutch newborn screening for congenital hypothyroidism by incorporating amino acids and acylcarnitines in a machine learning-based model. European Thyroid Journal, Oct 2023. URL: https://doi.org/10.1530/etj-23-0141, doi:10.1530/etj-23-0141. This article has 13 citations and is from a peer-reviewed journal.
(jansen2023optimizingthedutch pages 5-7): Heleen I Jansen, Marije van Haeringen, Marelle J Bouva, Wendy P J den Elzen, Eveline Bruinstroop, Catharina P B van der Ploeg, A S Paul van Trotsenburg, Nitash Zwaveling-Soonawala, Annemieke C Heijboer, Annet M Bosch, Robert de Jonge, Mark Hoogendoorn, and Anita Boelen. Optimizing the dutch newborn screening for congenital hypothyroidism by incorporating amino acids and acylcarnitines in a machine learning-based model. European Thyroid Journal, Oct 2023. URL: https://doi.org/10.1530/etj-23-0141, doi:10.1530/etj-23-0141. This article has 13 citations and is from a peer-reviewed journal.
(olivieri2025isittime pages 2-4): Antonella Olivieri, Maria Cristina Vigone, Mariacarolina Salerno, and Luca Persani. Is it time to expand newborn screening for congenital hypothyroidism to other rare thyroid diseases? International Journal of Neonatal Screening, 11:65, Aug 2025. URL: https://doi.org/10.3390/ijns11030065, doi:10.3390/ijns11030065. This article has 0 citations.
(peters2026retrospectivemulticentreevaluation pages 4-6): Catherine Peters, Claire Wood, James M. Law, Chloe Stevens, Fatemah Alhusaini, Darla Rigby, Hannah Hornby, Tim Cheetham, and Nadia Schoenmakers. Retrospective, multicentre evaluation of central congenital hypothyroidism in the uk. European Thyroid Journal, Apr 2026. URL: https://doi.org/10.1530/etj-26-0014, doi:10.1530/etj-26-0014. This article has 0 citations and is from a peer-reviewed journal.
(jansen2023optimizingthedutch pages 8-9): Heleen I Jansen, Marije van Haeringen, Marelle J Bouva, Wendy P J den Elzen, Eveline Bruinstroop, Catharina P B van der Ploeg, A S Paul van Trotsenburg, Nitash Zwaveling-Soonawala, Annemieke C Heijboer, Annet M Bosch, Robert de Jonge, Mark Hoogendoorn, and Anita Boelen. Optimizing the dutch newborn screening for congenital hypothyroidism by incorporating amino acids and acylcarnitines in a machine learning-based model. European Thyroid Journal, Oct 2023. URL: https://doi.org/10.1530/etj-23-0141, doi:10.1530/etj-23-0141. This article has 13 citations and is from a peer-reviewed journal.
(boelen2023neonatalscreeningfor media 77a8ab01): Anita Boelen, Nitash Zwaveling-Soonawala, Annemieke C Heijboer, and A S Paul van Trotsenburg. Neonatal screening for primary and central congenital hypothyroidism: is it time to go dutch? European Thyroid Journal, Jun 2023. URL: https://doi.org/10.1530/etj-23-0041, doi:10.1530/etj-23-0041. This article has 26 citations and is from a peer-reviewed journal.

Ask OpenScientist

OpenScientist Report

Inheritance

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Treatments

Biochemical Markers

Source YAML

References & Deep Research

Deep Research

Disease Characteristics Research Template

Target Disease

Research Objectives

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic/Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome/Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Citation Requirements

Output Format

Central Congenital Hypothyroidism (CCH) — Comprehensive Research Report

1. Disease information

2. Etiology

2.1 Disease causal factors

2.2 Risk factors

2.3 Protective factors / gene–environment interactions

3. Phenotypes (clinical presentation)

3.1 Core laboratory phenotype (diagnostic pattern)

3.2 Clinical phenotypes and frequencies (selected evidence)

4. Genetic / molecular information

4.1 Causal genes (isolated CCH)

4.2 Pathogenic variants (examples from 2024 literature)

4.3 Gene frequencies in recent cohorts

5. Environmental information

6. Mechanism / pathophysiology

6.1 Causal chain (high-level)

6.2 Cell types and processes (ontology suggestions)

7. Anatomical structures affected

8. Temporal development

9. Inheritance and population

9.1 Epidemiology

9.2 Inheritance

10. Diagnostics

10.1 Clinical tests / biomarkers

10.2 Pituitary evaluation (MPHD risk)

10.3 Screening (newborn screening; real-world implementations)

11. Outcome / prognosis

12. Treatment

12.1 Standard of care

12.2 Clinical trials / experimental therapies

13. Prevention

14. Other species / natural disease

15. Model organisms

Recent developments (prioritizing 2023–2024)

Current applications and real-world implementations

Summary table (evidence synthesis)

Key screening algorithm figure (Dutch strategy)

Evidence gaps / limitations of this run